Effects of amylin and the amylin agonist pramlintide on glucose metabolism

Diabetic Medicine

Volumn 14, Issue SUPPL. 2, 1997, Pages

  Schmitz, O ^a   Nyholm, B ^a   Orskov L ^a   Gravholt, C ^a   Moller N ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Amylin; Diabetes mellitus; Hypoglycaemia; Insulin resistance; Pramlintide

Indexed keywords

AMYLIN; PRAMLINTIDE;

ARTICLE; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFECT; ENZYME SUBSTRATE; GLUCONEOGENESIS; GLUCOSE METABOLISM; HORMONE RESPONSE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY;

EID: 0030737675     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9136(199706)14:2+3.3.co;2-w     Document Type: Article

References (29)

1. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreas of Type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628-8632.
2. Cooper GJS, Leighton B, Dimitriadis GD, et al. Amylin found in amyloid deposits in human Type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 1988; 85: 7763-7766.
3. Leighton B, Cooper GJ. The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus. Trends Biochem Sci 1990; 15: 295-299.
4. Young DA, Deems RO, Deacon RW, MacIntosh H, Foley JE. Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol 1990; 259: E457-E461.
5. Blackard WJ, Clore JN, Kellum JM. Amylin/insulin secretory ratios in morbidly obese man: inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab 1994; 78:1257-1260.
6. Bretherton-Watt D, Gilby SG, Ghatei MA, Baecham J, Bloom S. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 1990; 33: 115-117.
7. Bretherton-Watt D, Gilby SG, Ghatei MA, Baecham J, Macrae AD, Bloom S. Very high concentrations of islet amyloid peptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 1992; 74: 1032-1035.
8. Wilding JP, Khandan-Nia N, Bennet WM, et al. Lack of acute effect of amylin (islet-associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 1994; 37: 166-169.
9. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA. Postprandial hyperglycemia in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1986; 77: 1525-1532.
10. Pehling G, Tesari P, Gerich JE, Haymond MW, Service FJ, Rizza RA. Abnormal meal carbohydrate disposition in insulin-dependent diabetes. J Clin Invest 1986; 74: 985-991.
11. Deems RO, Deacon RW, Young DA. Amylin activates glycogen phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism. Biochem Biophys Res Commun 1991; 174: 716-720.
12. Young AA, Mott DM, Stone K, Cooper GJS. Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat. FEBS Lett 1991; 282: 149-151.
13. Young AA, Cooper GJS, Carlo P, Rink TJ, Wang M. Response to intravenous injections of amylin and glucagon in fasted, fed and hypoglycemic rats. Am J Physiol 1993; 264: E943-E950.
14. Young AA. Amylin regulation of fuel metabolism. J Cell Biochem 1994; 55S: 12-18.
15. Leighton B, Foot E. The effects of amylin on carbohydrate metabolism in skeletal muscle in vitro and in vivo. Biochem J 1990; 269: 19-23.
16. Zierath JR, Galuska D, Engstrom A, et al. Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in in vivo incubated muscle strips. Diabetologia 1992; 35: 26-31.
17. Molina JM, Cooper GJ, Leighton B, Olefsky JM. Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 1990; 39: 260-265.
18. Sowa R, Sanke T, Hirayama J, et al. Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 1990; 332: 118-120.
19. Koopmans SJ, van Mansfeld AD, Jansz HS, et al. Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues. Diabetologia 1991; 34: 218-224.
20. Kassir AA, Upadhyay AK, Lim TJ, Moossa AR, Olefsky JM. Lack of effect of islet amyloid polypeptide in causing insulin resistance in conscious dogs during euglycemic clamp studies. Diabetes 1991; 40: 998-1004.
21. Frontoni S, Choi SB, Banduch D, Rossetti L. In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 1991; 40: 568-573.
22. Pittner RA, Albrandt K, Beaumont K, et al. Molecular physiology of amylin. J Cell Biochem 1994; 55S: 19-28.
23. Betsholtz C, Christmansson L, Engstrom U, et al. Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett 1989; 251: 261-264.
24. Janes S, Gaeta L, Beaumont K, Beeley N, Rink T. The selection of pramlintide for clinical evaluation. Diabetes 1996; 45 (suppl 2): A865.
25. Nyholm B, Møller N, Gravholt CH, et al. Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 1083-1089.
26. Hwang JH, Perseghin G, Rothman DL, et al. Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 1995; 95: 783-787.
27. Ørskov L, Alberti KG, Mengel A, et al. Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 521-526.
28. Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM. Results of a multicenter trial. Diabetes 1997; 46: 632-636.
29. Kolterman OG, Gottlieb AB, Moyses C, Colburn W. Reduction of postprandial hyperglycaemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 1995; 18: 1179-1182.